How to use Technologies searched

A search for a company looking for a cancer, preclinical stage, synthetic opportunity would use the selection "Biomedicine, Diagnostics" in 'Sector', 'Cancerous, neoplasmatic' in 'Disease Category', 'Drugs, Small Molecule' in 'Technology' and 'Preclinical' in 'Development Stage'.

Selection of 'Enabling Technology, Platform technology' in 'Sector' will identify all kinds of searches for technologies that can be used in more areas of life sciences than pharmaceuticals only.

Each search profile gives the name or a short description of the company behind the search, and a link allowing to contact your potential licensee.

Registered users can create non-public notifications profiles which will inform them about new Technologies Searched entries fitting their expertise as specified. In addition these profiles allow them to filter the available information more comfortably.


Lilly is looking for opportunities in Neuroscience

Organization name

Global External Research & Development Lilly Research Laboratories Eli Lilly and Company



The vision at Lilly Research Laboratories, of which Global External R&D is a part, is a commitment to discovering, developing and acquiring innovative medicines to improve outcomes for individual patients.

Lilly Bio-Medicines is Lilly's largest business unit and is comprised of more than 20 countries, including the U.S. and Japan, the world's two largest pharmaceutical markets — along with Australia, Canada and Europe. They are home to Lilly's centralized marketing organization, which is leading development of capabilities, solutions and tools to ensure that all of Lilly delivers unparalleled customer experiences.

They are particularly interested in:


  • Depression- particularly those opportunities that address sexual side effects, weight gain, co-morbidities and treatment resistant patients
  • Schizophrenia- particularly those opportunities that address weight gain, negative symptoms and cognitive impairment
  • Bipolar disorders

Pain and Migraine:

  • Neuropathic, inflammatory and visceral (focus on chronic pain)
  • Migraine prophylaxis

Neurodegenerative diseases:

  • Alzheimer's disease: Approaches that affect disease progression or modification and/or address major symptoms of the disease
  • Parkinson's disease: Approaches that affect disease progression or modification and/or address major symptoms of the disease

Other areas of consideration:

  • ADHD, Sleep disorders, Autism, PTSD, Epilepsy

Currently out of scope unless clinical Phase 2 data is available in patients:

  • Anxiety, Substance abuse, and Orphan indications

Approaches currently out of scope:

  • SNRIs
  • SSRIs
  • Triptans
  • CB1 agonists
  • NGF Abs (pending 3/12 FDA decision)
  • Neurontin formulations
  • TRPV1 agonists/antagonists (unless improved tolerability, e.g. hyperthermeia, taste, pungency)
  • New formulations of marketed medicines (unless advanced Phase 2 or Phase 3 and differentiated)

To view the contact information, attachments and url of this profile you have to login into your account or register a new account: Login Register

Your feedback

Please click here to log in to view the complete profile.


latest entries